ClinicaliQ Trial Snapshot
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn’s Disease — Recruiting • Phase III • Rheumatology • NCT07184931.
- What is being tested: Duvakitug, a novel therapeutic agent, is undergoing Phase 3 evaluation for induction of remission in moderately to severely active Crohn's disease through a randomized, double-blind, placebo-controlled design across multiple international centres.
- Patient eligibility overview: The trial recruits adults with documented moderately to severely active Crohn's disease; specific inclusion/exclusion criteria (disease biomarkers, prior treatment history, comorbidities) would determine individual participant suitability and are detailed in the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 weeks with: * Up to 5-week Screening Period. * 12-week Sub-Study 1 (Single Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction). * 12-week Sub-Study 3 (Extended Induction for non-responders). * 6 weeks (45 days) follow-up period for participants who do not enroll into the Pivotal Maintenance…
Eligibility Snapshot
- : * Participants aged ≥18 and ≤80 years of age at Screening. Where permitted locally, participants 16 to
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.